The Janus faces of CD40 in cancer

Seminars in Immunology

Volumn 21, Issue 5, 2009, Pages 301-307

  Loskog, Angelica S I ^a   Eliopoulos, Aristides G ^b,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF CRETE   (Greece)

^c INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

Author keywords

Cancer; CD40; Pathogenesis; Therapy

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BCL2 RELATED PROTEIN A1; CANCER VACCINE; CD40 ANTIGEN; CD40 LIGAND; CP 870893; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOMYCIN C; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B; SGN 40; TAPASIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UNINDEXED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CARCINOMA; BREAST CANCER; BURKITT LYMPHOMA; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CARCINOMA; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; KIDNEY CARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PROSTATE CARCINOMA; REVIEW; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN REDNESS; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REGRESSION; VIRAL GENE THERAPY;

ANIMALS; ANTIGENS, CD40; HUMANS; NEOPLASMS;

EID: 70349148591     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2009.07.001     Document Type: Review

References (82)

1. Elgueta R., Benson M.J., de Vries V.C., Wasiuk A., Guo Y., and Noelle R.J. Molecular mechanism and function of CD40/CD154 engagement in the immune system. Immunol Rev 229 1 (2009) 152-172
2. O'Sullivan B., and Thomas R. CD40 and dendritic cell function. Crit Rev Immunol 23 1-2 (2003) 83-107
3. Callard R.E., Armitage R.J., Fanslow W.C., and Spriggs M.K. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol Today 14 (1993) 559-564
4. Zhang Y., Cao H.J., Graf B., Meekins H., Smith T.J., and Phipps R.P. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol 160 3 (1998) 1053-1057
5. Tan J., Town T., Mori T., Obregon D., Wu Y., DelleDonne A., et al. CD40 is expressed and functional on neuronal cells. EMBO J 21 4 (2002) 643-652
6. Young L.S., Eliopoulos A.G., Gallagher N.J., and Dawson C.W. CD40 and epithelial cells: across the great divide. Immunol Today 19 11 (1998) 502-505
7. Hollenbaugh D., Mischel-Petty N., Edwards C.P., Simon J.C., Denfeld R.W., Kiener P.A., et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med 182 1 (1995) 33-40
8. Bishop G.A., Moore C.R., Xie P., Stunz L.L., and Kraus Z.J. TRAF proteins in CD40 signaling. Adv Exp Med Biol 597 (2007) 131-151
9. Eliopoulos A.G. "Make and brake" in signaling. Science 321 5889 (2008) 648-649
10. Phipps R.P. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 97 13 (2000) 6930-6932
11. Noelle R.J., Mackey M., Foy T., Buhlmann J., and Burns C. CD40 and its ligand in autoimmunity. Ann NY Acad Sci 815 (1997) 384-391
12. Challa A., Eliopoulos A.G., Holder M.J., Burguete A.S., Pound J.D., Chamba A., et al. Population depletion activates autonomous CD154-dependent survival in biopsylike Burkitt lymphoma cells. Blood 99 9 (2002) 3411-3418
13. Pham L.V., Tamayo A.T., Yoshimura L.C., Lo P., Terry N., Reid P.S., et al. A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity 16 1 (2002) 37-50
14. van den Oord J.J., Maes A., Stas M., Nuyts J., Battocchio S., Kasran A., et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol 149 6 (1996) 1953-1961
15. Tong A.W., Papayoti M.H., Netto G., Armstrong D.T., Ordonez G., Lawson J.M., et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 7 3 (2001) 691-703
16. Bussolati B., Russo S., Deambrosis I., Cantaluppi V., Volpe A., Ferrando U., et al. Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet-activating factor synthesis. Int J Cancer 100 6 (2002) 654-661
17. Baxendale A.J., Dawson C.W., Stewart S.E., Mudaliar V., Reynolds G., Gordon J., et al. Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene 24 53 (2005) 7913-7923
18. Tai Y.T., Podar K., Mitsiades N., Lin B., Mitsiades C., Gupta D., et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 101 7 (2003) 2762-2769
19. Chiodoni C., Iezzi M., Guiducci C., Sangaletti S., Alessandrini I., Ratti C., et al. Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med 203 11 (2006) 2441-2450
20. Vanichakarn P., Blair P., Wu C., Freedman J.E., and Chakrabarti S. Neutrophil CD40 enhances platelet-mediated inflammation. Thromb Res 122 3 (2008) 346-358
21. Stunz L.L., Busch L.K., Munroe M.E., Sigmund C.D., Tygrett L.T., Waldschmidt T.J., et al. Expression of the cytoplasmic tail of LMP1 in mice induces hyperactivation of B lymphocytes and disordered lymphoid architecture. Immunity 21 2 (2004) 255-266
22. Eliopoulos A.G., and Young L.S. LMP1 structure and signal transduction. Semin Cancer Biol 11 6 (2001) 435-444
23. Homig-Holzel C., Hojer C., Rastelli J., Casola S., Strobl L.J., Muller W., et al. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med 205 6 (2008) 1317-1329
24. Hayward A.R., Levy J., Facchetti F., Notarangelo L., Ochs H.D., Etzioni A., et al. Cholangiopathy and tumours of the pancreas, liver and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 158 (1997) 977-983
25. Cantwell M., Hua T., Pappas J., and Kipps T.J. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 3 9 (1997) 984-989
26. Hock B.D., McKenzie J.L., Patton N.W., Drayson M., Taylor K., Wakeman C., et al. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer 106 10 (2006) 2148-2157
27. Skibola C.F., Nieters A., Bracci P.M., Curry J.D., Agana L., Skibola D.R., et al. A functional TNFRSF5 gene variant is associated with risk of lymphoma. Blood 111 8 (2008) 4348-4354
28. French R.R., Chan H.T.C., Tutt A.L., and Glennie M.J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T cell help. Nat Med 5 (1999) 548-553
29. Diehl L., den Boer A.T., Schoenberger S.P., van der Voort E.I., Schumacher T.N., Melief C.J., et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 5 7 (1999) 774-779
30. Sotomayor E.M., Borrello I., Tubb E., Rattis F.M., Bien H., Lu Z., et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 5 7 (1999) 780-787
31. Mackey M.F., Gunn J.R., Maliszewski C., Kikutani H., Noelle R.J., and Barth R.J. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res 57 13 (1997) 2569-2574
32. Grossmann M.E., Brown M.P., and Brenner M.K. Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther 8 16 (1997) 1935-1943
33. Kato K., Cantwell M.J., Sharma S., and Kipps T.J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 101 5 (1998) 1133-1141
34. Kikuchi T., and Crystal R.G. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther 10 (1999) 1375-1387
35. Sun Y., Peng D., Lecanda J., Schmitz V., Barajas M., Qian C., et al. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther 7 17 (2000) 1467-1476
36. Dzojic H., Loskog A., Totterman T.H., and Essand M. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 66 8 (2006) 831-838
37. Loskog A., Bjorkland A., Brown M.P., Korsgren O., Malmstrom P.U., and Totterman T.H. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol 166 3 (2001) 1093-1097
38. Kikuchi T., Moore M.A.S., and Crystal R.G. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against pre-existing murine tumors. Blood 96 (2000) 91-99
39. Urashima M., Suzuki H., Yuza Y., Akiyama M., Ohno N., and Eto Y. An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium. Blood 95 4 (2000) 1258-1263
40. Turner J.G., Rakhmilevich A.L., Burdelya L., Neal Z., Imboden M., Sondel P.M., et al. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol 166 1 (2001) 89-94
41. Lum H.D., Buhtoiarov I.N., Schmidt B.E., Berke G., Paulnock D.M., Sondel P.M., et al. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol 79 6 (2006) 1181-1192
42. Vardouli L, Lindqvist C, Vlahou K, Loskog AS, Eliopoulos AG. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Cancer Gene Ther; in press.
43. Loskog A., Dzojic H., Vikman S., Ninalga C., Essand M., Korsgren O., et al. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol 172 11 (2004) 7200-7205
44. Loskog A.S., Fransson M.E., and Totterman T.T. AdCD154 gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 11 24 Pt 1 (2005) 8816-8821
45. Kotowicz K., Dixon G.L., Klein N.J., Peters M.J., and Callard R.E. Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes. Immunology 100 4 (2000) 441-448
46. Li G., Sanders J.M., Bevard M.H., Sun Z., Chumley J.W., Galkina E.V., et al. CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol 172 4 (2008) 1141-1152
47. Cromme F.V., Airey J., Heemels M.T., Ploegh H.L., Keating P.J., Stern P.L., et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 179 1 (1994) 335-340
48. Khanna R., Cooper L., Kienzle N., Moss D.J., Burrows S.R., and Khanna K.K. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol 159 12 (1997) 5782-5785
49. Lou Y., Vitalis T.Z., Basha G., Cai B., Chen S.S., Choi K.B., et al. Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res 65 17 (2005) 7926-7933
50. Dissemond J., Kothen T., Mors J., Weimann T.K., Lindeke A., Goos M., et al. Downregulation of tapasin expression in progressive human malignant melanoma. Arch Dermatol Res 295 2 (2003) 43-49
51. Hill S.C., Youde S.J., Man S., Teale G.R., Baxendale A.J., Hislop A., et al. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 174 1 (2005) 41-50
52. Donepudi M., Quach D.D., and Mokyr M.B. Signaling through CD40 enhances cytotoxic T lymphocyte generation by CD8+ T cells from mice bearing large tumors. Cancer Immunol Immunother 48 2-3 (1999) 153-164
53. Moschonas A., Kouraki M., Knox P.G., Thymiakou E., Kardassis D., and Eliopoulos A.G. CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1. Mol Cell Biol 28 20 (2008) 6208-6222
54. Ghia P., Transidico P., Veiga J.P., Schaniel C., Sallusto F., Matsushima K., et al. Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood 98 3 (2001) 533-540
55. Funakoshi S., Longo D.L., Beckwith M., Conley D.K., Tsarfaty G., Tsarfaty I., et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83 10 (1994) 2787-2794
56. Henriquez N.V., Floettmann E., Salmon M., Rowe M., and Rickinson A.B. Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus Latent Membrane Protein 1. J Immunol 162 (1999) 3298-3307
57. Baker M.P., Eliopoulos A.G., Young L.S., Armitage R.J., Gregory C.D., and Gordon J. Prolonged phenotypic, functional and molecular changes in group I Burkitt lymphoma cells on short term exposure to CD40 ligand. Blood 92 (1998) 2830-2843
58. Szocinski J.L., Khaled A.R., Hixon J., Halverson D., Funakoshi S., Fanslow W.C., et al. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood 100 1 (2002) 217-223
59. Chu P., Deforce D., Pedersen I.M., Kim Y., Kitada S., Reed J.C., et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99 6 (2002) 3854-3859
60. Andersen N.S., Larsen J.K., Christiansen J., Pedersen L.B., Christophersen N.S., Geisler C.H., et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood 96 (2000) 2219-2225
61. Lee H.H., Dadgostar H., Cheng Q., Shu J., and Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 96 16 (1999) 9136-9141
62. Hennino A., Berard M., Krammer P.H., and Defrance T. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J Exp Med 193 4 (2001) 447-458
63. Benson R.J., Hostager B.S., and Bishop G.A. Rapid CD40-mediated rescue from CD95-induced apoptosis requires TNFR-associated factor-6 and PI3K. Eur J Immunol 36 9 (2006) 2535-2543
64. Eliopoulos A.G., Dawson C.W., Mosialos G., Floettmann J.E., Rowe M., Armitage R.J., et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13 (1996) 2243-2254
65. von Leoprechting A., van der Bruggen P., Pahl H.L., Aruffo A., and Simon J.C. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 59 6 (1999) 1287-1294
66. Ghamande S., Hylander B.L., Oflazoglu E., Lele S., Fanslow W., and Repasky E.A. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 61 20 (2001) 7556-7562
67. Hirano A., Longo D.L., Taub D.D., Ferris D.K., Young L.S., Eliopoulos A.G., et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93 9 (1999) 2999-3007
68. Davies C.C., Mason J., Wakelam M.J., Young L.S., and Eliopoulos A.G. Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J Biol Chem 279 2 (2004) 1010-1019
69. Hess S., and Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J Exp Med 183 (1996) 159-167
70. Eliopoulos A.G., Davies C., Knox P.G., Gallagher N.J., Afford S.C., Adams D.H., et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 20 15 (2000) 5503-5515
71. Grell M., Zimmermann G., Gottfried E., Chen C.-M., Grunwald U., Huang D.C.S., et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J 18 (1999) 3034-3043
72. Afford S.C., Ahmed-Choudhury J., Randhawa S., Russell C., Youster J., Crosby H.A., et al. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface Fas ligand expression and amplifies Fas-mediated hepatocyte death during allograft rejection. J Exp Med 189 (1999) 441-446
73. Georgopoulos N.T., Steele L.P., Thomson M.J., Selby P.J., Southgate J., and Trejdosiewicz L.K. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 13 10 (2006) 1789-1801
74. Bugajska U., Georgopoulos N.T., Southgate J., Johnson P.W., Graber P., Gordon J., et al. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst 94 18 (2002) 1381-1395
75. Wierda W.G., Cantwell M.J., Woods S.J., Rassenti L.Z., Prussak C.E., and Kipps T.J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96 9 (2000) 2917-2924
76. Biagi E., Rousseau R., Yvon E., Schwartz M., Dotti G., Foster A., et al. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res 11 19 Pt 1 (2005) 6916-6923
77. Rousseau R.F., Biagi E., Dutour A., Yvon E.S., Brown M.P., Lin T., et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD154 and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 107 4 (2006) 1332-1341
78. Dessureault S., Noyes D., Lee D., Dunn M., Janssen W., Cantor A., et al. A phase-I trial using a universal GM-CSF-producing and CD154-expressing bystander cell line (GM.CD154) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol 14 2 (2007) 869-884
79. Vonderheide R.H., Dutcher J.P., Anderson J.E., Eckhardt S.G., Stephans K.F., Razvillas B., et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 19 13 (2001) 3280-3287
80. Forero-Torres A., Furman R.R., Rosenblatt J.D., Younes A., Harrop K., and Drachman J.G. A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): results of a phase 1 study. J Clin Oncol 24 (2006) 430s
81. Vonderheide R.H., Flaherty K.T., Khalil M., Stumacher M.S., Bajor D.L., Hutnick N.A., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25 7 (2007) 876-883
82. Gomes E.M., Rodrigues M.S., Phadke A.P., Butcher L.D., Starling C., Chen S., et al. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res 15 4 (2009) 1317-1325